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Abstract: Hazard ratios (HRs) are used commonly to report results
from randomized clinical trials in oncology. However, they remain
one of the most perplexing concepts for clinicians. A good under-
standing of HRs is needed to effectively interpret the medical
literature to make important treatment decisions. This article pro-
vides clear guidelines to clinicians about how to appropriately
interpret HRs. While this article focuses on the commonly used
methods, the authors acknowledge that other statistical methods
exist for analyzing survival data.
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WHAT IS A HAZARD RATIO?
Hazard ratios are frequently used to estimate the treatment
effect for time-to-event end points, such as overall survival (OS)
and progression-free survival (PFS), in oncology randomized
clinical trials (RCTs). A time-to-event analysis (also and from
this point on called a survival analysis) analyzes the time from
the start of a study (e.g., randomization) to an event (e.g., death
for OS). Before discussing hazard ratios (HRs), key concepts
related to understanding survival data are reviewed.
A Kaplan-Meier (KM) curve (also called a survival
curve or a KM analysis) is used to estimate survival and
presents survival data. The curve represents the proportion of
patients event-free (e.g., alive for OS) at any time. The curve
is not smooth, but actually a series of downward steps
occurring each time a patient has an event (e.g., death in an
OS curve). At any time point in an OS analysis, patients can
have only one of the following events: (i) death, (ii) continue
to be monitored, or (iii) stop being monitored (i.e., they are
censored). Patients who are censored have not had an event as
of the end of the observation period, and it is unknown
whether they will have an event in the future. There are
several reasons why censoring can occur; typically it is
because patients are still alive at the end of the study or are lost
to follow-up.1 Reasons for censoring and censoring patterns
should be closely examined as they may impact interpretation of
the results. Regardless of how the censoring rules are defined in
a given RCT, the intention is to incorporate all data collected on
patients while they were participating in the study.
A HR provides an estimate of the ratio of the hazard
rates between the experimental group and a control group
over the entire study duration. The hazard rate is the rate of
patients experiencing the event of interest over a short time
interval within each of the treatment arms in the study. This
concept can be illustrated by a hypothetical example: an RCT
with two treatment arms and a primary end point of OS
(Table 1). During the first week, the rate of patients dying is
higher in the control arm (0.04) than in the experimental arm
(0.03). In the second week, the rate of patients dying is
double than that in the first week: 0.08 for patients in the
control arm and 0.06 for patients in the experimental arm. The
HR (experimental versus control) is calculated for each week by
dividing the rate of patients dying in the experimental arm by the
rate of patients dying in the control arm. Although the hazard
rate changes over time, the HR is approximately constant
(0.75) for each week (Table 1). Hence, the HR reported for
this RCT would be 0.75 because a constant HR is calculated
over the entire duration of the trial.
The HR is usually calculated from a Cox proportional
hazards model, which is one of the standard methods for
analyzing survival end points in oncology RCTs.2 A simplis-
tic interpretation is that a HR 1 means equal efficacy of the
experimental and control treatments (Figure 1). Usually, the
HR is presented so that if the experimental treatment is (i)
better than the control then the HR 1 or (ii) worse than the
control then the HR 1.
WHY ARE HAZARD RATIOS USEFUL?
The log-rank and Wilcoxon tests are commonly used to
compare the entire survival data over the duration of the trial,
between treatment arms; they do not compare the medians or
time point estimates. However, these methods only generate
a p value and not an estimate of the magnitude or direction of
the treatment effect (i.e., these methods assess whether sur-
vival between the two treatment arms was significantly dif-
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ferent but not how it was different). That is, the log-rank and
Wilcoxon tests only determine whether the treatments are
different (or not) but do not indicate how much one treatment
is better or worse than the other.
The three main ways of estimating the magnitude and
direction for survival outcomes from RCTs are (i) the HR, (ii)
by reporting the median survival for each treatment arm, and
(iii) time point analyses (e.g., proportion of patients alive at 1
and 2 years for each treatment arm in an OS analysis).
Medians and time point estimates are often generated from
the KM analysis (Box 1). Sometimes differences between
treatments in medians, or in the time points of 1 or 2 years,
are also presented. From these, the magnitude and direction
of the treatment effect can be estimated. However, HRs differ
from the other two measures in the following ways.
First, the HR summarizes all the information in the
entire KM survival curves, and hence summarizes the treat-
ment effect over the entire duration of a RCT (Figure 2). In
contrast, median survival focuses on only one point on the
survival curve for each treatment arm (Figure 2). In reality,
the median survival is the expected (not observed) time when
half of the patients will have had an event (i.e., died for OS)
and half will not (i.e., still be alive for OS). The median OS
estimates from prospective RCTs are unfortunately some-
times interpreted by individual patients as their precise esti-
mated life expectancy with no corresponding interval for the
expected variability in survival around that.3 It is important to
stress that median survival represents at best a “group aver-
age” and is overly simplistic as a measure of an individual
patient’s duration of disease control or OS. Hence, two lines
on a KM curve can have the same median survival but look
different before and after the median (Figure 3C).
Second, the HR provides an estimate of the relative
efficacy between the treatment arms (e.g., HR  0.75 for an
OS end point means on average approximately a 25% lower
risk of death on the experimental treatment than the control,
Box 2). In contrast, comparing medians for each treatment
TABLE 1. Concept of Calculating of a Hazard Ratio
Time Period Treatment Arm
No. Patients
at Riska (B)
No. Died
During Time
Period (A)
No. Patients Dropped
Out During Time
Periodb
Rate of Patients Dyingc
(Calculated as A/B)
Proportion of the Rate of
Patients Dying in Experimental
Arm Compared with Control Armd
First week Experimental 100 3 0 0.03 0.75
Control 100 4 0 0.04
Second week Experimental 97 6 3 0.06 0.74
Control 96 8 1 0.08
Third week Experimental 88 9 1 0.10 0.74
Control 87 12 2 0.14
To precisely calculate the hazard ratio, the Cox proportional hazards model must be used, which accounts for the censoring times.
a Patients who are alive and still in the study at the start of the time period.
b Censored patients.
c Hazard rate for the time period (results shown are rounded to 2 decimal places).
d Hazard ratio (E vs C) for the time period. Please note that results shown are rounded to 2 decimal places, but the calculations used the raw numbers from the previous
column (c) and therefore give different results than if the rounded numbers were used (eg, 0.06/0.08  0.75).
FIGURE 1. Simplistic interpretation of a hazard ratio (HR).
HR  1 means equal efficacy of the experimental (E) and
control (C) treatments. If the experimental treatment is bet-
ter than the control, then the HR (E versus C) 1. If the ex-
perimental treatment is worse than the control, then the HR
(E versus C) 1.
BOX 1. Hazard Ratio vs Median Survival and Time Point
Estimates
Hazard Ratio Median Survival Time Point Estimates
Relative efficacy measure Absolute efficacy
measure
Absolute efficacy
measure
Summarizes the treatment
effect over the entire
duration of a RCT, i.e.,
uses all of the
information in the
whole KM curve
Compares the survival
time at one point on
the KM curve only
Compares the survival
time at one point on
the KM curve only
(e.g., 1 yr)
Superiority and
noninferiority trial
designs are usually
based on the HR
Claims of superiority
can be misleading.
Superiority and
noninferiority trial
designs are
generally based on
the HR and not the
median
Claims of superiority
can be misleading.
Superiority and
noninferiority trial
designs are
generally based on
the HR and not an
estimate at a
specific time point
Unadjusted and adjusted
HRs can be generated
from univariate and
multivariate Cox
proportional hazards
models, respectively
Unadjusted Unadjusted
Calculated using a Cox
proportional hazards
model
Calculated by reading
the survival time of
a KM curve when
the survival
probability is 50%
Calculated by reading
the survival
probability on a
KM curve at the
time point of
interest (e.g., 1 yr)
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arm provides an absolute measure of any improvement in
efficacy (e.g., 2 months difference in the median survival)
relative to a particular absolute median for the control group.
Other absolute measures of improved efficacy between the
treatment arms include the proportion surviving at defined
time points (e.g., such as 1-year OS probability). Third, due
to the two properties outlined above, claims of superiority
and noninferiority are recommended to be made based on the
HR and not the median. Time point analyses also encounter
these three issues as described for the median survival.
Finally, adjusted and unadjusted HRs can be calculated.
The aim of randomization is for both known and unknown
prognostic factors to be balanced between the treatment arms.
However, even when well-designed randomization tech-
niques are conducted, imbalances may occur by chance alone.
In such situations, analyses adjusted for known prognostic
factors are recommended to account for the imbalances.4 If
there are no major imbalances in known prognostic factors,
the adjusted and unadjusted analyses should produce similar
results. Of note, although KM survival curves can be pre-
sented for subsets of patients with particular baseline prog-
nostic factors, they are generally not adjusted for baseline
prognostic factors (statistical methods are available for gen-
erating adjusted survival curves). Therefore, the median sur-
vival and survival probabilities at defined time points (e.g.,
1-year OS probability) derived from KM survival curves are
also unadjusted. The unadjusted HR summarizes all the
information displayed graphically in the KM survival curves
(Figure 2). An unadjusted HR is calculated from a univariate
Cox proportional hazards model that only contains treatment
(e.g., E versus C) as a covariate, whereas adjusted HRs are
typically performed using the multivariate Cox model, i.e., it
also contains the covariates that will be adjusted for, such as
FIGURE 2. Median survival versus the hazard ratio (HR).
Kaplan-Meier (KM) curves are used to graphically describe
time-to-event (survival) outcomes in randomized clinical tri-
als (RCTs). Above is a KM curve from a hypothetical oncol-
ogy RCT of two treatment (Trt) arms (Trt A and Trt B) which
evaluated overall survival (OS) as the primary end point. The
KM curves plot the “events” that occur in each treatment
arm. For OS, death is the event so the curve drops down a
“step” each time a patient dies to reflect the new probability
of still being alive at that point in time in each treatment
arm. The HR summarizes all the time-to-event information
described by the KM survival curve. In contrast, the median
survival focuses on only one point on the KM curve, that is
the survival time when survival probability is 50% (shown by
the dotted lines).
FIGURE 3. The Proportional Hazards (PH) assumption. Pro-
portional hazards assumption holds true (A), minor violation
of the PH assumption (B), and major violation of the PH as-
sumption (C). TRT, treatment.
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age, gender, disease stage, and performance status.2 If base-
line prognostic factors are not balanced, then adjusted sur-
vival curves can be constructed to display the expected
survival in each treatment arm. There are several available
methods to generate the adjusted survival curves, such as the
“average covariate” method.5 These are distinct to the KM
method and beyond the scope of this article.
WHAT ARE THE LIMITATIONS?
Correct interpretation of a HR is based on the assump-
tion that the ratio of the hazard rates at each time interval is
approximately constant during the study. This is also known
as the “Proportional Hazards” (PH) assumption. In the hypo-
thetical example described above (Table 1), the PH assump-
tion held true as the ratio of the hazard rates (0.75) was
approximately constant for each time interval over the dura-
tion of the trial. Hence, the HR can be correctly interpreted as
patients on the experimental arm having on average approx-
imately a 25% lower risk of death than those in the control
arm at any point in time during the trial (Box 2). Determining
whether or not the PH assumption holds true can be deter-
mined by formal statistical tests and plots, e.g., Martingale
residuals, Schoenfeld residuals versus survival time,6 and
log-negative-log plots. However, it can usually be reliably
established from reviewing the shape of the KM survival
curves, and thus the results of formal tests are rarely reported
in the literature. If the separation between the curves is
maintained over time, then the PH assumption is likely to
hold true (Figure 3A). Mild decrease or increase in separation
over time is likely to be a minor violation of the PH assump-
tion. One possibility when the KM curve is separated
throughout most of the trial but comes together at the end
is that by this time the survival data are very mature because
there are few patients still at risk as most of the patients have
already died or been censored. Given the poor survival in
most cancers, if a trial continues long enough, the curves will
often come together as advanced cancers are usually not
curable, regardless of what therapy is received. In contrast, in
other cancers in which a substantial proportion of patients do
survive for longer than the follow-up period, the survival
curves may plateau because after this time patients are un-
likely to die of the primary cancer (e.g., treatment for high-
grade lymphoma). Fortunately, most oncology clinical trials
produce KM survival curves that are fairly consistent with the
PH assumption. Goodness-of-fit assessment for the Cox
model should also be performed.
HOW TO INTERPRET A HAZARD RATIO
As discussed earlier, a simplistic interpretation is that if
the HR (E versus C) is 1, then the experimental treatment
is better than the control and vice versa if HR (E versus C)
1. The following examples illustrate more detailed expla-
nations and common pitfalls.
Appropriate Interpretation
Suppose the HR (E versus C)  0.75 from a trial
evaluating OS where the PH assumption held true (Figure
3A). This can be interpreted as either (i) on average approx-
imately a 25% lower risk of death (25% as 1  0.75  0.25)
or (b) on average approximately a 33% improvement in
survival time (33% as 1/0.75 1.33) in the experimental arm
compared with the control arm at any point during the trial
(Box 2). Note that this is on average (assuming an exponen-
tial distribution of the survival data), so any such improve-
ment or reduction in survival should be interpreted in the
context of the KM curve as a whole.
The reduction in the risk of death is lower than the
percent increase in survival time (i.e., a ratio). If the log HR
is taken, then the same magnitude of benefit is observed for
both interpretations. For example, log 0.750.125 and log
1.33  0.125, so the log magnitude of benefit (i.e., 0.125) is
the same for both interpretations.
Inappropriate Interpretation and Common
Mistakes
Crossing Survival Curves
If the HR (i.e., the treatment effect) varies over time
and changes in magnitude but not in direction (Figure 3B),
then this is likely a minor violation of the PH assumption.
The Cox proportional hazards model is widely accepted as
being robust to minor violations of the PH assumption, and
the overall HR can be interpreted as an average HR over time.
If there is a major violation of the PH assumption
(Figure 3C), then it is inappropriate to interpret the overall
HR, even as an average over time, because the HR varies so
significantly over time (e.g., the treatment effect changes
direction). In such cases, there is interest in understanding for
which patients the experimental treatment is better than the
control and for which patients the experimental treatment is
worse than the control, and/or whether there is a time-
dependent treatment effect. For example in Figure 3C, the
treatment A is better than treatment B for the first 9 months
of the trial when the curves cross. Hence, the HR (A versus
B) is 1 up to this point. However, after the curves cross, the
treatment A is worse than treatment B and so the HR (A
versus B) is  1 after 9 months. In this situation, it should
also be investigated by performing subgroup analyses if there
is a qualitative interaction driving the curves to cross for the
population as a whole (e.g., is the HR in males in the opposite
direction and statistically significantly different to the HR in
females?)7 If a significant qualitative interaction is identified,
then the KM curves for each level of the subgroup (e.g.,
males and females) should be reviewed to identify whether
the PH assumption holds true in these subsets. If this is the
case, then interpretation should be focused on these subsets of
BOX 2. Interpretation of a Hazard Ratio
HR (E vs C)  0.75 for an overall survival end point
This means on average, under an exponential distribution, approximately
● a 25% lower risk of death (25% as 1  0.75  0.25)
● a 33% increase in survival time (33% as 1/0.75  1.33)
On the experimental treatment compared with the control at any point
during the trial
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patients in light of existing evidence for this subgroup effect,
rather than on the all randomized patient population. In
addition, efficacy claims for the all randomized patients
population should also be avoided. In this case, as with any
subgroup analysis, claims of superiority within a subset of
patients cannot be made unless the subgroup analysis was
prespecified, a statistically significant interaction was ob-
served, and there is sufficient confirmatory evidence to vali-
date the subgroup effect.
Magnitude Matters
The HR is a relative measure. Hence, a statistically
significant p value (p  0.05) associated with the HR (E
versus C)  0.75 may be obtained, meaning that (i) the
experimental treatment is superior or inferior to the control
arm and (ii) there is at most a 5% chance of observing an
effect of this magnitude or more extreme (e.g., 0.75) by
chance if there is no difference between the treatments. This
would seem a positive result for patients. However, whether
this is clinically significant also needs to be evaluated. To do
this, clinicians will likely need to assess the absolute im-
provement in survival time by examining absolute measures
such as the survival rates at fixed time points (e.g., 1-, 2-, and
3-year survival probabilities) and the median survival. These
absolute measures only focus on one point of the survival
curve and so can be misleading if they are considered indi-
vidually. However, collectively they describe the KM curve.
Hence, clinicians should look for consistent clinically mean-
ingful improvements across these absolute measures. For
example, if a HR  0.75 corresponds to an increase in the 1-
and 2-year OS rate of 10% and 20%, respectively, between
the treatment arms in an advanced non-small cell lung cancer
trial, these might be deemed clinically meaningful improve-
ments. If the median survival difference between arms is next
considered, then an improvement of 50 days may also be
regarded as clinically significant, whereas an improvement of
approximately 10 days may not. Only if the descriptive
absolute measures reveal a fairly consistent pattern of clini-
cally meaningful improvements should a statistically signif-
icant HR be hailed as a clinical advancement.
Extrapolation of The HR Beyond The Study
Duration
Using the HR reported for a RCT to predict what
happens after the duration of the study should be done with
great caution and is generally not recommended. This is
because HRs summarize the treatment effect over the ob-
served duration of a RCT. The duration of a clinical trial is
from when the first patient is randomized to the last patient
visit. In the absence of subsequent information, it is not
possible to conclusively determine whether the proportional
hazards assumption would continue to hold true. In addition,
the effect of subsequent interventions on the treatment effect
beyond the trial duration is also not accounted for. This is
pertinent in the metastatic setting where subsequent lines
of therapy or palliative care will heavily influence a
patient’s survival probability. Statistical techniques exist
for extrapolating the HR beyond the duration of a RCT,
which can be used in cost-effectiveness analyses, but these
techniques rely on strong assumptions and are beyond the
scope of this article.
SUMMARY
The Cox proportional hazards model is used to analyze
survival data. It provides a HR to assess the relative efficacy
of the experimental treatment compared with the control
treatment over the duration of the RCT. As with everything
else in clinical medicine, results of testing statistical hypoth-
eses and estimating treatment effect should always be inter-
preted keeping the clinical significance in mind. These sta-
tistical tests after all are only means to the noble goal of
uncovering the truth and improving the lives of our patients
by providing useful treatment and avoiding needless exposure
to ineffective or questionably effective therapies.
ACKNOWLEDGMENTS
The authors thank Nancy Iturria for generating simu-
lated survival data to create the survival curve figures and
Jonathon Denne and Mauro Orlando for critically reviewing
the article and providing helpful comments.
REFERENCES
1. Altman DG, Bland JM. Time to event (survival) data. BMJ 1998;317:
468–469.
2. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat
Methodol 1972;34:187–220.
3. Gould SJ. The median isn’t the message. Discover 1985;6:40–42.
4. European Agency for the Evaluation of Medicinal Products (EMEA),
Committee for Proprietary Medicinal Products (CPMP). Points to con-
sider on adjustment for baseline covariates. CPMP/EWP/283/99, 2003.
5. Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review
and a new method. Am J Epidemiol 1996;143:1059–1068.
6. Schoenfeld D. Partial residuals for the proportional hazards regression
model. Biometrika 1982;69:239–241.
7. Barraclough H, Govindan R. Biostatistics primer: what a clinician ought
to know: subgroup analyses. J Thorac Oncol 2010;5:741–746.
Barraclough et al. Journal of Thoracic Oncology • Volume 6, Number 6, June 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer982
